-       Clinical Trials 
- April 2025
-  60 Pages 
- Global 
   From       €1073EUR$1,200USD£944GBP 
      €1342EUR$1,500USD£1,180GBP 
            -       Clinical Trials 
- April 2025
-  90 Pages 
- Global 
   From       €1073EUR$1,200USD£944GBP 
      €1342EUR$1,500USD£1,180GBP 
            -       Clinical Trials 
- April 2025
-  90 Pages 
- Global 
   From       €1073EUR$1,200USD£944GBP 
      €1342EUR$1,500USD£1,180GBP 
          -       Report 
- September 2025
-  150 Pages 
- Global 
   From       €3444EUR$3,850USD£3,029GBP 
          -       Report 
- October 2025
-  391 Pages 
- Global 
   From       €4292EUR$4,799USD£3,776GBP 
             -       Report 
- October 2025
-  182 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  191 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  182 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  190 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- April 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- April 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- April 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- March 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
            -       Drug Pipelines 
- July 2025
-  280 Pages 
- Global 
   From       €2147EUR$2,400USD£1,888GBP 
      €2683EUR$3,000USD£2,360GBP 
            -       Clinical Trials 
- April 2025
-  120 Pages 
- Global 
   From       €2147EUR$2,400USD£1,888GBP 
      €2683EUR$3,000USD£2,360GBP 
            -       Clinical Trials 
- April 2025
-  60 Pages 
- Global 
   From       €2147EUR$2,400USD£1,888GBP 
      €2683EUR$3,000USD£2,360GBP 
       
      The Cluster of Differentiation 3 (CD3) market is a subset of the oncology drug market that focuses on drugs that target the CD3 molecule. CD3 is a protein found on the surface of T-cells, which are a type of white blood cell that plays a key role in the body's immune system. CD3-targeting drugs are used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. These drugs work by blocking the CD3 molecule, which prevents the T-cells from attacking healthy cells and helps to    reduce the growth of cancer cells.
Some of the companies in the CD3 market include Novartis, Merck, Pfizer, and Bristol-Myers Squibb. These companies have developed a range of CD3-targeting drugs, including Imbruvica, Keytruda, and Opdivo. These drugs have been approved by the FDA for the treatment of various types of cancer and are widely used in the oncology field. Show Less   Read more